相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
Christina M. Annunziata et al.
BLOOD (2011)
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
Douglas W. McMillin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
Sally A. Hunsucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo et al.
CLINICAL CANCER RESEARCH (2011)
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
Michael. S. van der Veer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
A. Scuto et al.
LEUKEMIA (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease
Yong Liang et al.
MEDICAL HYPOTHESES (2011)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Yulia N. Demchenko et al.
BLOOD (2010)
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Kihyun Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells
Pavel Krejci et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea et al.
MOLECULAR CANCER THERAPEUTICS (2010)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
L. Santo et al.
ONCOGENE (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa et al.
BLOOD (2009)
Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Teru Hideshima et al.
BLOOD (2009)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti et al.
BLOOD (2009)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Dexin Kong et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
Shuang Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Joan M. Carboni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA
Steffan T. Nawrocki et al.
BLOOD (2008)
Cul4A is required for hematopoietic cell viability and its deficiency leads to apoptosis
David L. Waning et al.
BLOOD (2008)
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Ya-Wei Qiang et al.
BLOOD (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma
Peter M. Voorhees et al.
CLINICAL CANCER RESEARCH (2007)
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
Jianfei Qian et al.
BLOOD (2007)
Targeting MEK induces myelorna-cell cytotoxicity and inhibits osteoclastogenesis
Yu-Tzu Tai et al.
BLOOD (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
Simona Colla et al.
BLOOD (2007)
Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma
Kumar Sukhdeo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel et al.
CLINICAL CANCER RESEARCH (2007)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo
Teru Hideshima et al.
CLINICAL CANCER RESEARCH (2006)
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Suzanne Trudel et al.
BLOOD (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
DR Carrasco et al.
CANCER CELL (2006)
Antimyeloma activity of heat shock protein-90 inhibition
CS Mitsiades et al.
BLOOD (2006)
Perspectives for combination therapy to overcome drug-resistant multiple myeloma
L Catley et al.
DRUG RESISTANCE UPDATES (2005)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
N Raje et al.
BLOOD (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
H Chang et al.
BLOOD (2005)
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Cytokines and signal transduction
T Hideshima et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
PWB Derksen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway
A Niida et al.
ONCOGENE (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
Y Kawaguchi et al.
CELL (2003)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
N Mitsiades et al.
BLOOD (2003)
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
G Bisping et al.
BLOOD (2003)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
J Shaughnessy et al.
BLOOD (2001)
分享论文
